Somatic Symptom Disorders in Patients With Myocardial Bridge
NCT04664387
Cardiovascular Abnormalities, Cardiovascular Diseases
Shanghai, China
View Trial DetailsNCT Number: NCT05111418
Myocardial bridge (MB) is a congenital anomaly of epicardial circulation characterized by an intramural course of a coronary segment. This anatomical arrangement causes the artery to be squeezed during systole potentially causing flow impairment and ischemia. For this study, MB is defined as the presence of systolic compression in an epicardial vessel causing at least 50% of caliber reduction from diastole. MB can be disabling as it worsens the quality of life. Early detection of this congenital condition is crucial, and an invasive functional assessment of the ischemic burden should be considered to evaluate the need for medical or surgical therapy.
This is an observational study, involving four Italian centres. Study Objectives are: To assess the risk of future cardiovascular complications in patients with MB referred for coronary angiography and the role of beta-blocker therapy; To describe the clinical and anatomical characteristics of patients presenting with MB; To determine the impact of cardiovascular medications on symptoms in patients with MB; To describe the anatomical and clinical features associated with the invasive evidence of ischemia in patients with MB; To assess the relation between invasively documented ischemia and clinical manifestations in patients with the MB. Inclusion Criteria: patients referred to undergo ICA (for both elective or urgent indications) for suspected coronary artery disease found to have an MB with or without other epicardial lesions amenable to revascularization; Age above 18 y.o.; Ability to provide Informed Consent. Exclusion Criteria are Patients with life expectancy below 12 months and Patients with severe valvular heart disease. The primary endpoint is the incidence of MACE defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization, and target vessel revascularization. The secondary endpoint is evaluating the Rate of patients with SAQ < 70 and the Rate of patients with "high-risk features" on CT scan.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Arcispedale S. Anna, Azienda Ospedaliero - Universitaria di Ferrara, Ferrara, Italia, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years follow up
Incidence of MACE defined as the composite of cardiac death, myocardial infarction, cardiac hospitalization and target vessel revascularization
Time frame: 2 years follow up
Time frame: 2 years follow up
High risk features
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Acronym: RIALTO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04664387
Cardiovascular Abnormalities, Cardiovascular Diseases
Shanghai, China
View Trial DetailsNCT04958395
Cardiovascular Abnormalities, Cardiovascular Diseases
View Trial DetailsNCT06857838
Angina Pectoris, Angina, Stable
Xi'an, Shaanxi, China
View Trial DetailsNCT06281067
Cardiovascular Abnormalities, Cardiovascular Diseases
Acquaviva delle Fonti, Italy
View Trial Details